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Policy and Practice
Averting a malaria disaster in Africa — where does the
buck stop?
Christopher J.M. Whitty,1 Richard Allan,2 Virginia Wiseman,1 Sam Ochola,3 Maria Veronicah Nakyanzi-Mugisha,4
Benjamin Vonhm,5 Mahemba Mwita,6 Constantin Miaka,7 Aggrey Oloo,8 Zul Premji,9 Craig Burgess,10
& Theonest K. Mutabingwa11, 1

Abstract The serious threat posed by the spread of drug-resistant malaria in Africa has been widely acknowledged. Chloroquine
resistance is now almost universal, and resistance to the successor drug, sulfadoxine-pyrimethamine (SP), is growing rapidly.
Combination therapy has been suggested as being an available and potentially lasting solution to this impending crisis. However, the
current cost of combination therapy, and especially that of artemisinin combination therapy (ACT), is potentially a serious drawback,
even if a signiﬁcant part of its cost is passed on to the end-user. If the question of cost is not successfully addressed this could lead
to adverse results from the deployment of combination therapy as ﬁrst-line treatment. These adverse effects range from an increase
in potentially fatal delays in infected individuals presenting to medical services, to exclusion of the poorest malaria sufferers from
receiving treatment altogether. Urgent steps are needed to reduce the cost of combination therapy to the end-user in a sustainable
way if it is to be usable, and some possible approaches are discussed.
Keywords Malaria, Falciparum/drug therapy; Antimalarials/economics; Drug therapy, Combination; Artemisinins/economics; Drug
costs; Patient acceptance of health care; Financing, Organized; Africa (source: MeSH, NLM).
Mots clés Paludisme plasmodium falciparum/chimiothérapie; Antipaludique/économie; Polychimiothérapie; Artemisinines/économie;
Coût médicament; Acceptation des soins; Organisation ﬁnancement; Afrique (source: MeSH, INSERM).
Palabras clave Paludismo falciparum/quimioterapia; Antimaláricos/economía; Quimioterapia combinada; Artemisininas/economía;
Costos en drogas; Aceptación de la atención de salud; Organización (fuente: DeCS, BIREME).
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Voir page 383 le résumé en français. En la página 384 ﬁgura un resumen en español.

Drug-resistant malaria — the gathering storm
The serious threat posed by drug-resistant malaria in Africa is
widely acknowledged (1). Chloroquine resistance is now universal, and the days of treating malaria with a single cheap drug
are generally believed to be numbered. Resistance to sulfadoxinepyrimethamine (SP) the natural successor to chloroquine was
increasing by the end of the 1990s. It was argued then that the
only way to protect this or any other single drug is to give it in
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combination with another unrelated antimalarial as combination drug therapy (CDT) as in the case of tuberculosis (TB)
treatment (1). Since the 1990s, the accelerating emergence and
spread of resistance to SP has been documented in many areas,
with parasitological failure rates of around 20% being widely
reported, and up to 40–80% in certain areas (2, 3). Two relatively cheap drugs could potentially replace SP as monotherapy;
amodiaquine (an older drug with similarities to chloroquine)
and chlorproguanil-dapsone (Lapdap, an anti-folate). Both are
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currently effective in many areas where SP resistance already
occurs, but this situation may well not last for much longer (2, 4).
Resistance to amodiaquine already exists at an appreciable level in
some areas (up to 26% in Kenya) (5). Because of its similarity to
SP, there is a concern that resistance to chlorproguanil-dapsone
may follow rapidly if it is deployed widely in areas of widespread
SP resistance. We therefore face a crisis in treating malaria
which is one of the most important causes of morbidity and
mortality in Africa. The proposed CDT has received widespread
scientiﬁc support and has the potential for returning Africa to
sustainable, highly effective antimalarial treatment. The solution has, however, one serious drawback.
It has been suggested for some years that combinations
of drugs, and especially combinations that include artemisinin
drugs, will be highly effective in treating malaria. There is indirect
evi-dence from south-east Asia (but not from Africa) that these
combinations could also delay or halt the emergence of drug
resistance. An informal expert consultation held by WHO in 2001
supported the conclusion that combinations of drugs are the best,
and possibly the only, long-term solution (6). Setting aside the
question of cost, the consultation proposed a list of three artemisinin-containing combinations (lumefantrine–artemether,
amodiaquine–artesunate and SP–artesunate) that they considered
to have the greatest potential, and one non-artemisinin combination (SP–amodiaquine) was suggested as a fall-back option.
Subsequent studies have conﬁrmed that these combinations are
highly effective and safe (4, 5). A number of technical questions
(for example on local effectiveness and safety in pregnancy)
have yet to be answered and operational studies are required.
One potential advantage of artemisinins, namely that they reduce
transmission by reducing gametocyte carriage (7), has not been
conﬁrmed in Africa and may not be relevant in areas with high
transmission of malaria.
The principle that combination therapy could provide a
rapid solution to a serious crisis and do so in a sustainable manner
has, however, gained widespread support.

Cost — the major ﬂaw
There remains a serious problem with combination therapy, and
that is its cost (1, 8, 9). Chloroquine and SP cost approximately
US$ 0.15 for a course of treatment. Negotiation between the
WHO and some drug companies has already successfully reduced the cost of combination treatment to between US$ 0.90
and US$ 1.4 for a course of treatment for children up to seven
years old and to approximately US$ 2 per adult dose. There are
theoretical reasons for assuming that the cost might fall over
time (10), but it seems unlikely to fall substantially below that
negotiated by WHO in the immediate future, and making policy
based on the assumption that cost may fall signiﬁcantly is rash.
It is well established that combination therapies are more expensive than current monotherapy and that the true opportunity
cost of switching to combination therapy will signiﬁcantly exceed
current drug price estimates. Therefore, issues of affordability
can no longer be disregarded. The potential cost of combination
therapy was viewed as “disastrous” in 1998 (11), a “major obstacle” in 2000 (8), a “serious challenge” in 2001 (12), a “critical
factor” in 2002 (9), and we still face a crisis in 2004.
In many parts of Africa a family member may have malaria
several times per year, and febrile episodes treated as malaria more
often still. A household may therefore have to pay for malaria
treatment many times a year. If household income is only a few
dollars a month, increasing the cost of malaria treatment with
combination therapy even by US$ 0.5 will have grave consequences, both direct and indirect.
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At this cost, the poorest members of society will not be
able to afford malaria treatment at all. Increasing user fees has
been shown to have the potential to discriminate against the
group in society whose health needs are greatest and who can
therefore least afford to be deterred from seeking health care
(13, 14). Malaria is particularly a disease of the poor and of
populations affected by long-term conﬂict. One-third of the
annual deaths from malaria worldwide occur in African countries
affected by conﬂict (15). In one such area, up to 75% of the
population were reported as being unable to afford even a full
course of chloroquine from ofﬁcial health facilities or private
markets (16). Consequently poorer parents already buy incomplete treatment or divide a full course of drugs between several
family members. This results in treatment failure, increased selection pressure for drug resistance and increased prevalence of
severe anaemia.
The problems of signiﬁcantly increased costs are not restricted to people who cannot pay at all. Parents faced with high
treatment costs commonly delay bringing their children or themselves for treatment until they are sure of the diagnosis. By this
time the patient is often too sick to be treated successfully. It is
the delay in receiving adequate treatment that kills many people
with malaria. With prompt diagnosis and treatment with an efﬁcacious drug, most cases of malaria are entirely curable.
Other malaria sufferers will be put off going to formal
medical services if the costs of drugs are too high and will seek
their treatment from the informal sector where much antimalarial treatment is already provided, often inappropriately (17).
The effects of cost are not always predictable; in some instances
ﬁnancial cost has had little effect on access to treatment or
on adherence, but elsewhere it has played an important role
in deterring people from attendance at antenatal clinics and
hospitals (18).
Increased cost also has wider public health implications.
The incentive to produce counterfeit drugs increases with the
price at which they can be sold. Counterfeit antimalarials are
only beginning to be a problem in Africa where low-cost drugs
are used for ﬁrst-line treatment (19), but the problem is reaching
serious proportions in south-east Asia where artemisinin-containing combinations are in use (20).

Two conﬂicting, but correct positions
On the one hand there are drugs universally accepted to be
close to ideal for the treatment of malaria. On the other hand,
deploying these drugs as ﬁrst-line treatment if more than a
fraction of the current cost is passed on to households, may
prevent, delay or divert effective treatment-seeking behaviour.
The public health impact of using these excellent drugs may
even be worse than that of using a less effective but cheaper
drug. Trying to pretend that there is no conﬂict is pointless
— both positions are correct: combination therapy probably
is the best solution, but deploying combination drugs at their
current or foreseeable cost could be at best inequitable and at
worst actively harmful.
The only way to reconcile these two positions is to provide
combination therapy at a cost to households that is no greater
than that of current malaria treatment, or better still, to provide
treatment free of charge. This would render irrelevant all the
current concerns about deploying combination therapy once
the remaining technical issues have been addressed.
As there are only a few relatively well-deﬁned ways that
this could be achieved, the technical questions to be answered
are also relatively well deﬁned.
Bulletin of the World Health Organization | May 2004, 82 (5)
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Cost — some solutions will not work

Subsidy — the only realistic option

We have already discussed the reasons why transferring the increased cost burden to individuals will fail, regardless of whether
the drugs were bought on the market or through a revolving
drug fund or user fee. Published evaluations of user and drug-fee
schemes suggest that they have been easier to impose than to
enforce or sustain. The regressive nature of these fees continues
to undermine the success of this type of health ﬁnancing policy
(21, 22). Social insurance schemes would also be likely to fail, as
those people most often affected by malaria are least often covered by insurance. In their review on rural risk-sharing schemes,
Creese & Bennet (23) reported that schemes in low-income
countries generally have only limited coverage, low cost-recovery
rates and little ability to protect the most needy.
Individual governments in the affected countries, many of
which are also coping with the twin epidemics of AIDS and TB,
would rightly say that improvements in the medical and diagnostic
infrastructure must take priority when allocating their limited
resources. Malaria remains a severe economic burden on most of
these countries, reducing GDP by up to 18% (24), and, therefore,
dealing with it effectively should be an economic as well as a
humanitarian priority. Diagnostic facilities for malaria do already
exist, although as with TB and HIV services, the diagnostic services
for malaria in many areas need to be strengthened signiﬁcantly
as a matter of priority, especially if more expensive drugs are to
be used. In areas with low endemicity of malaria such improvements may include considering the use of new malaria dipsticks,
although these have severe technical limitations in areas of high
endemicity. Improving diagnostic infrastructure is necessary
irrespective of which drugs are used, although with more expensive drugs, improved rational use of drugs increases their costeffectiveness.
However, the burden of subsidizing the drug costs is almost
certainly unrealistically high for the governments of countries
with a high endemicity of malaria to bear. Put in perspective, the
entire health care budget of a country such as Rwanda is around
US$ 10 million. According to recent estimates, this might just
cover the cost of changing malaria treatment (10). Malaria is a
problem that is not going to disappear with investment, so loans
are not appropriate. In the many countries of Africa affected
by long-term conﬂicts, bank loans and bilateral grants are not
even an option. This limits the available choices. Although some
of the countries in which malaria is endemic may be able to
contribute signiﬁcantly towards the solution to the growing
malaria treatment crisis with both material and management
resources, most cannot meet the costs of more expensive drugs
without assistance.

Support from pharmaceutical companies and donors has an
important role to play, but if combination therapy for malaria
is to be deployed, the international donor community would
have to make a major and indeﬁnite commitment to buying or
subsidizing the drugs so that the cost to the end-user is low or
non-existent. This could mean subsidizing indigenous production, subsidizing the drugs before they arrive in countries in
which malaria is endemic, or supporting low-cost production.
Subsidy up to the point that the costs of combination therapy are
equivalent to the costs of the currently used drugs is one option,
but the provision of free drugs has many additional advantages.
Ironically drug treatment for malaria is free in almost all middleincome and high-income countries — but not in the poorest.
Strong political support will also be essential at country level to
ensure that low-cost or free malaria treatment provided at the
centre remains so to health providers and malaria patients.
The provision of free drugs would be a bold step, but not
without precedent. Several excellent TB and leprosy control
programmes have worked on the basis of free (donated) drug
programmes. Such a programme would be achievable over a
short period of time as the basic infrastructure already exists
and the drugs are licensed. Few of the operational problems
that have been highlighted for antiretroviral treatment for
HIV/AIDS in Africa (25) would occur with malaria because
treatment courses are relatively short, and there is no need for
follow-up and monitoring. The Global Fund to Fight AIDS,
Tuberculosis and Malaria potentially provides a mechanism that
could be used to fund malaria drugs sustainably, without relying
on a single donor (26).

Conclusion
Combination drug therapy offers a safe and effective potential
solution to the spread of drug-resistant malaria which is one of
the great public health crises looming over Africa. Unless the real
cost considerations of combination drug therapy are met, this
urgently needed new therapeutic approach can never achieve
its full potential. Attempting to deploy combination therapy as
ﬁrst-line treatment without addressing this problem could paradoxically make things worse for the poorest and most vulnerable
malaria sufferers. The solution is, ultimately, a political rather
than a scientiﬁc one. This is not an issue that can be ignored,
and the speed of onset of the crisis means that ﬁnding a solution cannot be delayed. O
Conﬂicts of interest: none declared.

Résumé
Eviter une catastrophe liée au paludisme en Afrique : quel compromis ?
La grave menace que constitue la propagation du paludisme
pharmacorésistant en Afrique est largement reconnue. La
résistance à la chloroquine est maintenant presque générale et
la résistance à la sulfadoxine-pyriméthamine, le successeur de la
chloroquine, gagne rapidement du terrain. On a émis l’idée que
la polychimiothérapie pouvait représenter une solution accessible
et peut-être durable à cette crise imminente. Cependant, le coût
actuel d’un tel traitement, en particulier lorsqu’il comporte une
artémisinine, risque d’être un inconvénient majeur, même s’il est
supporté pour une grande partie par le patient lui-même. Si l’on
Bulletin of the World Health Organization | May 2004, 82 (5)

ne résout pas la question du coût du traitement, l’adoption de
la polychimiothérapie comme traitement de première intention
risque d’avoir des conséquences fâcheuses, allant du décès de
malades qui auront attendu trop longtemps avant de faire appel
aux services médicaux, à l’exclusion des malades les plus pauvres
de tout traitement. Il est urgent de prendre des mesures pour
réduire durablement le coût de la polychimiothérapie pour le
patient si l’on veut qu’elle soit applicable ; certaines orientations
sont proposées.
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Resumen
Malaria en África: delimitar las responsabilidades para evitar una catástrofe
La grave amenaza planteada por la propagación de la malaria
farmacorresistente en África es un problema ampliamente
reconocido. La resistencia a la cloroquina es ya casi universal, y la
resistencia al medicamento sucesor, la sulfadoxina-pirimetamina
(SP), está extendiéndose rápidamente. Se ha sugerido el recurso a
la politerapia como solución disponible y potencialmente duradera
para esta crisis inminente. Sin embargo, el actual costo de la
politerapia, especialmente el de las combinaciones basadas en la
artemisinina (PA), constituye un posible inconveniente grave, aun
cuando una parte signiﬁcativa de ese costo se traslade al usuario.

Si no se aborda satisfactoriamente ese problema, el despliegue
de la politerapia como tratamiento de primera línea podría
conducir a resultados adversos, desde un aumento de los retrasos
potencialmente mortales en la búsqueda de atención médica por
los individuos infectados, hasta la exclusión total del tratamiento
de los enfermos de malaria más pobres. Se requieren medidas
urgentes a ﬁn de reducir el costo de la politerapia para el usuario
de manera sostenible y hacer así viable esa opción, y se examinan
aquí algunas de las posibles estrategias en esa línea.
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